The cardiovascular burden of end-stage renal disease patients

Minerva Urologica e Nefrologica

Volumn 62, Issue 1, 2010, Pages 51-65

  Cianciolo, G ^a   Donati, G ^a   La Manna, G ^a   Ferri, A ^a   Cuna, V ^a   Ubaldi, G ^a   Corsini, S ^a   Lanci, N ^a   Coli L ^a   Stefoni, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cardiovascular diseases; Kidney diseases; Kidney failure, chronic

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; FOLIC ACID; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PLATELET DERIVED GROWTH FACTOR AB; SODIUM THIOSULFATE; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN B GROUP; WARFARIN;

BLOOD VESSEL CALCIFICATION; BODY MASS; BONE TURNOVER; CALCINOSIS; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DEBRIDEMENT; DIALYSIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; METABOLIC BONE DISEASE; PATHOGENESIS; PHOSPHATE METABOLISM; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; THROMBOSIS; UREMIA; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

CALCINOSIS; CALCIPHYLAXIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 77953486644     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Stefoni S, La Manna G, De Sanctis LB, Dalmastri V, Perna C, Pace G et al. Clinical biology of artificial organ substitution. Nephrol Dial Transplant 1998;13(Suppl 7):51-4. (Pubitemid 28534774)
2. United States Renal Data System. Atlas of end stage renal disease in the United States. Volume II [Internet]. [cited 2010 February 24]. Available at: http://www.usrds.org/2009/slides/indiv/INDEX-ESRD.HTML
3. RIDT - Società Italiana di Nefrologia. Registro italiano di dialisi e trapianto [Internet]. [cited 2010 February 24]. Available at: http://www.sin-ridt.org/sin-ridt.org.htm
4. Pastan S, Bailey J. Dialysis therapy. N Eng J Med 1998;338:1428-37.
5. De Jager D, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D et al. Cardiovascular and non cardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-9.
6. Euroaspire II Study Group. Lifestyle and risk factor management and use of drugs therapies in coronary patients from 15 countries; principal results from Euroaspire II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
7. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69.
8. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999;340:115-26.
9. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005;352;1685-95.
10. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation 2002;106:136-40.
11. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-58.
12. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-911. (Pubitemid 29197978)
13. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
14. Cianciolo G, La Manna G, Colì L, Donati G, D'Addio F, Persici E et al. 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol 2008;28:941-8.
15. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M et al. IL-10, IL-6, TNF-a: central factors in the altered cytokine network of uremia The good, the bad, the ugly. Kidney Int 2005;67:1216-33.
16. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002;62;949-55.
17. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C et al. Interleuchin-6 is a stronger predictor of a total and cardiovascular mortality than C-reactive protein in hemodialysis patients. Nephrol Dial Transplant 2004;19:1154-60.
18. Barreto DV, Barretto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C et al. Plasma interleuchin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2009 Epub ahead of print].
19. Nelson PR, Yamamura S, Kent KC. Plateled derived growth factor and extracellular matrix proteins provide a synergistic stimulus for human vascular smooth miscle cell migration. J Vasc Surg 1997;26:104-12.
20. Cianciolo G, Stefoni S, Donati G, De Pascalis A, Iannelli S, Manna C et al. Intra- and post-dialytic platelet activation and PDGF-AB release: cellulose diacetate vs polysulfone membranes. Nephrol Dial Transplant 2001;16:1222-9.
21. KraÊniak A, Drozdz M, Pasowicz M, Chmiel G, Micha?ek M, Szumilak D et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007;22:515-21.
22. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR et al. The serum concentration of active transforming growth factor beta is severely depressed in advanced atherosclerosis. Nat Med 1995;1:74-9.
23. Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Colì L et al. Low TGF-1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002;61:324-35.
24. Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJ, Balakrishnan VS; HEMO Study Group. Transforming growth beta 1 gene polymorphism and cardiovascular disease in hemodialysis patients. Kidney Int 2004;66:419-27.
25. McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-9.
26. Buccianti G, Baragetti I, Bamonti I, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end stage renal disease. J Nephrol 2004;17:405-10.
27. Nygård O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995;274:1526-33.
28. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg H. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001;12:2181-91.
29. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004;15:442-53.
30. Nair AP, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J et al. Elevated homocysteine levels in patients with end stage renal disease. Mt Sinai J Med 2005;72:365-73.
31. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine ad a risk factor for cardiovascular disease in patients treated by dialysis. A meta-analysis. Am J Kidney Disease 2009;54:478-89.
32. Martì-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events (Review). Cochrane Database Syst Rev 2009;7:CD006612.
33. Nitta K, Akiba T, Suzuki K, Uchida K, Ogawa T, Majima K et al. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004;27:527-33.
34. Giachelli C. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14:S300-S4.
35. KDIGO Clinical practice guidelines for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int 2009;76(Supp 113):S1-S129.
36. O'Neill WC. Vascular calcification: not so crystal clear. Kidney Int 2007;71:282-3.
37. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al. Coronary artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Eng J Med 2000;342:1478-83.
38. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8:54-8.
39. Block G, Klassen PS, Lazarous JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
40. O'Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007;72:792-6.
41. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK et al. Cardiac calcification in adult hemodialysis patients. J Am Coll Cardiol 2002;39:695-701.
42. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on hemodialysis. Nephrol Dial Transplant 2006;21:1915-20.
43. Coen G, Ballanti P, Mantella D, Manni M, Lippi B, Pierantozzi A et al. Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study. Am J Nephrol 2009;29:145-52.
44. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int 2005;67:1576-82.
45. Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA et al. Association of changes in bone remodelling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis 2008;52:1139-50.
46. Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML et al. Coronary calcifications in end stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Blood Purif 2010;29:13-22.
47. Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD et al. Association of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutri 2006;83:202-10.
48. Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and rat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 2008;23:2461-6.
49. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57.
50. Jono S, Shioi A, Ikari Y, Nishizawa Y. Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006;24:176-81.
51. Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-70.
52. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009;22:774-82.
53. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-9.
54. Yao Y, Shahbazian A, Boström KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res 2008;102:1065-74.
55. Canfield AE, Farrington C, Dziobon MD, Boot-Handford RP, Heagerty AM, Kumar SN et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 2002;196:228-34.
56. Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004;91:790-4.
57. Jahnen-Dechent W, Schäfer C, Ketteler M, McKee MD. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J Mol Med 2008;86:379-89.
58. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007;115:2533-9.
59. Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 2006;26:423-9.
60. Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003;18:1152-8.
61. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J et al. Serum Fetuin-A in non-dialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005;67:1070-7.
62. Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, Braun S et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) 2008;68:660-5.
63. Wang M, Mei W, Liang Y, Li SJ, Hong N, Zhang M. Vascular calcification in maintenance hemodialysis patients. Blood Purif 2009;28:15-20.
64. Kirkpantur A, Altun B, Hazirolan T, Akata D, Arici M, Kirazli S et al. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Artif Organs 2009;33:844-54.
65. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M et al. Fibroblast Growth Factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006;17:1305-15.
66. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-6.
67. Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T et al. Role of growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006;17:1506-13.
68. Rogers NM, Coates PTH. Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypert 2008;17:629-34.
69. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002;61:2210-7.
70. Norris B, Vaysman V, Lyne BR. Bone scintigraphy of calciphylaxis: a syndrome of vascular calcification and skin necrosis. Clin Nucl Med 2005;30:725-7.
71. Hayden MR, Tyagj SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulphate. Cardiovasc Diabetol 2005;4:4-26.